Investor Presentation Q1 2023

124 North America Operations growth has accelerated Investor presentation First three months of 2023 DKK billion 1% 100 60 80 60 60 40 40 20 20 NAO 21% 41% 91 North America Operations reported sales growth per therapy area 3% 14% 67 60 60 61 0 2019 CER: Constant exchange rate Source: Quarterly company announcement 2020 2021 GLP-1 Insulin Other diabetes Obesity care Rare disease 29 2022 Q1 2023 Growth at CER

View entire presentation